New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients: AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.
Syn-Med-Chemist-"Quintessential Synthetic Chemistry"---A Synthetic Chemist's Perception......
No comments:
Post a Comment